Health Canada Issues Recall of Merck Canada / Intervet Canada Corp`s ORBAX (Orbifloxacin)
Aug 13 (Reuters) - U.S. drugmaker Merck & Co Inc (MRK.N) has initiated a rolling submission to Health Canada for Molnupiravir, an oral antiviral therapy treatment for COVID-19, it said in a statement on Friday.
With Merck & Co.’s current chief financial officer, Rob Davis, slated to take over as CEO, the New Jersey pharma has found his replacement in a long-serving employee.
Drug discovery software developer, Optibrium, has entered into a collaboration with MSD (known as Merck & Co. in the United States) for the integration of Optibrium’s software into MSD’s drug discovery infrastructure.
KIRKLAND, QC, Sept. 24, 2020 /CNW/ - Merck Canada Inc., an affiliate of Merck & Co., Inc., known as MSD outside the United States and Canada, announced today that NEXPLANON® (etonogestrel implant) 68 mg, a hormonal contraceptive implant, is now available in Canada.1 The implant, approved by Health Canada for the prevention of pregnancy for up to three years, provides Canadians with a progestin-only contraceptive option that is long-acting.1
Clovis Oncology Inc said on Friday the U.S. Food and Drug Administration has approved its drug Rubraca for the treatment of adult patients with metastatic castration-resistant prostate cancer, whose tumors have a genetic mutation.
Health Canada Issues Recall of Merck Canada Inc`s Marvelon 21
As pharma's earnings reports rolled out for the second quarter, market watchers pointed out a big positive: Growth rates, for many companies at least, were up. Way up.
Health Canada Issues Recall of Merck Canada Auro-Irbesartan Keytruda for IV infusion
The pharmaceutical industry, which is not at all happy about how lower courts have interpreted U.S. Supreme Court precedent on federal preemption of state law claims by people alleging injuries from pharma products, got a jolt of good news Monday from the high court. The justices asked the U.S. solicitor general to weigh in on Merck’s petition for Supreme Court review of a ruling from the 3rd U.S. Circuit Court of Appeals that makes it “virtually impossible,” in Merck’s words, for drug companies to win dismissal of personal injury suits by citing the Food and Drug Administration’s oversight of drug labeling.